Clinical Trials Sponsored by Natera, Inc.

Total 36463 results

Patara Pharma

Completed

Treatment of Indolent Systemic Mastocytosis With PA101

Systemic Mastocytosis | Mastocytosis | Indolent Systemic Mastocytosis

France, Germany, Spain, Italy, Netherlands
Anthera Pharmaceuticals

Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes (FRANCIS-ACS)

Acute Coronary Syndrome

Russian Federation, Georgia, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

Sickle Cell Disease | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Materna Laboratories

Unknown

Infant Formula Supplemented With Probiotic Microorganisms and/or Prebiotic.

Focus on Healthy Infant Growth.

Israel
Anthera Pharmaceuticals

Terminated

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16)

Acute Coronary Syndrome

United States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
Natural Calm Canada
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

Bioavailability of Magnesium Supplements

Healthy | Magnesium Deficiency

Canada
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Terminated

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study (MEADOWSPRING)

COVID-19 | Long COVID

Denmark, Switzerland, Turkey, Belgium, Mexico, Brazil, Argentina, Germany, Romania, Ukraine
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

COVID-19

Spain, Canada, United Kingdom, Greece, Ireland, Latvia
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

Healthy Volunteers Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Study of AT-527 in Healthy Subjects (R07496998)

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

Healthy Volunteer Study

Canada
Nayera Hassanien Mohamed

Unknown

Effect of Using Different Varnishes on Dentin Hypersensitivity; Na Fluoride and Nano-silver Fluoride

Dentin Hypersensitivity
Water Pik, Inc.
All Sum Research Center Ltd.

Completed

Efficacy of the Addition of a Power Interdental Device to an Electric Toothbrush on Gingival Health.

Gingivitis

Canada
All Sum Research Center Ltd.
Water Pik, Inc.

Completed

Water Flosser vs String Floss vs Manual Toothbrush Safety

Soft Tissue Injuries
Natural Cycles

Completed

NC Thermometer (Gen 3) ISO 80601-2-56 Validation

Healthy | Fever | Febrile Illness

United States
Assisting Nature

Unknown

Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol

Pregnancy, Ovarian

Greece
Assisting Nature

Unknown

Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol

Pregnancy, Ovarian

Greece
Assisting Nature

Unknown

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

Pregnancy, Ovarian

Greece
Anthera Pharmaceuticals

Completed

EASY: Extended Access to Sollpura Over Years

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Czechia
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
Anthera Pharmaceuticals

Terminated

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus

Georgia
Anthera Pharmaceuticals

Completed

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus (CHABLIS-SC1)

Systemic Lupus Erythematosus

Georgia, Belarus, Brazil, Colombia, Guatemala, Hong Kong, India, Korea, Republic of, Malaysia, Mexico, Philippines, Russian Federation, Singapore, Sri Lanka, Taiwan, Thailand
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Anthera Pharmaceuticals

Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive Crisis

United States
Materna Laboratories

Completed

Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital

Premature Infants

Israel
Anthera Pharmaceuticals

Completed

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

Coronary Artery Disease (CAD)

United States, Ukraine
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

Healthy Volunteer Study

Canada
Nayera Hazaa Elsherif

Completed

The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

Idiopathic Thrombocytopenic Purpura

Egypt
Indonesia University
Medika Natura Sdn Bhd

Completed

Dose-ranging Study of SKF7™ for Obesity

Obesity

Indonesia
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries

Cognitive Disorders

Russian Federation
Materia Medica Holding

Completed

Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children

Specific Developmental Disorders of Scholastic Skills

Russian Federation
Materia Medica Holding

Suspended

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Influenza

Russian Federation
Materia Medica Holding

Completed

Efficacy and Safety of Tenoten in the Treatment of Children With Anxiety Disorders

Anxiety Disorder of Childhood

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection

Viral Respiratory Infection

Russian Federation
Natural Wellness Egypt

Completed

A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus

Erectile Dysfunction

Egypt
Materia Medica Holding

Completed

Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2

Immunization Against COVID-19

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients

Obesity

Russian Federation
Entera Bio Ltd.

Completed

A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

Osteoporosis

Israel
Materia Medica Holding

Completed

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

Preventive Medicine

Russian Federation, Uzbekistan
Materia Medica Holding

Completed

Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

Influenza

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus

Type II Diabetes Mellitus

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

Acute Upper Respiratory Tract Infections

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients

Obesity

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression

Benign Prostatic Hyperplasia

Russian Federation, Ukraine

Clinical Trials Sponsored by Natera, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations